

Burosumab for treating X-linked hypophosphataemia in children and young people

Information for the public

Published: 10 October 2018

Last updated: 20 September 2024

www.nice.org.uk

Burosumab (Crysvita) is available on the NHS. It is a possible treatment for X-linked hypophosphataemia when there is radiographic evidence of bone disease in babies, children and young people aged 1 to 17 years.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

These organisations can give you advice and support:

- [XLH UK](#)
- [Metabolic Support UK](#) (formerly CLIMB), 0845 241 2173

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6503-8